Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16585460 | 0.84 | CYP3A4 (1.00) | CYP3A4TSHRNFKB1BLMPMP22 | |
| SCHEMBL29389441 | 0.84 | CYP3A4 (1.00) | CYP3A4TSHRNFKB1BLMPMP22 | |
| SCHEMBL16585151 | 0.84 | CYP3A4 (1.00) | CYP3A4TSHRNFKB1BLMPMP22 | |
| SCHEMBL918591 | 0.82 | ADORA3 (0.69) | CYP3A4TSHRNFKB1BLMPMP22 | |
| SCHEMBL20424012 | 0.82 | CYP3A4 (0.58) | CYP3A4TSHRNFKB1BLMPMP22 | |
| SCHEMBL6466865 | 0.82 | SLC29A1 (0.75) | CYP3A4TSHRNFKB1BLMPMP22 | |
| SCHEMBL6445165 | 0.81 | ADORA3 (0.78) | CYP3A4TSHRNFKB1BLMPMP22 | |
| SCHEMBL17825968 | 0.81 | SLC29A1 (1.00) | CYP3A4TSHRSLC29A1ADORA3LMNA | |
| SCHEMBL20626395 | 0.81 | SLC29A1 (1.00) | CYP3A4TSHRSLC29A1ADORA3LMNA | |
| SCHEMBL20626394 | 0.81 | SLC29A1 (1.00) | CYP3A4TSHRSLC29A1ADORA3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513848-A4 | METHOD OF TREATING ISCHEMIA REPERFUSION INJURY USING ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN IDEC INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050203065-A1 | Method of treating ischemia reperfusion injury using adenosine receptor antagonists | SMITS GLENN J (US) | 2005-09-15 | — | — | US | disclosed |
| EP-1513848-A2 | METHOD OF TREATING ISCHEMIA REPERFUSION INJURY USING ADENOSINE RECEPTOR ANTAGONISTS | Biogen Idec MA Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003105666-A2 | METHOD OF TREATING ISCHEMIA REPERFUSION INJURY USING ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| EP-1069126-B1 | TRIAZOLOPURINE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVES, ADENOSINE A3 RECEPTOR COMPATIBILIZING AGENT, AND ASTHMATIC REMEDY | OTSUKA PHARMA CO LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-1069126-A1 | TRIAZOLOPURINE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVES, ADENOSINE A3 RECEPTOR COMPATIBILIZING AGENT, AND ASTHMATIC REMEDY | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203065-A1 | Method of treating ischemia reperfusion injury using adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | CYP3A4 3840/4885TSHR 628/4885NFKB1 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.